| |
Cardiovascular markers (regression outcome) |
| Inflammation biomarkers
(log-transformed regression predictor) |
Isoprostane-to-Creatinine ratio |
Augmentation Index |
Reactive Hyperemia Index |
QTc |
RMSSD |
Triangular Index |
Low frequency variations |
High frequency variations |
Power Ratio |
Systolic blood pressure |
Diastolic blood pressure |
Heart rate |
| C-reactive protein |
0.01,
p=0.95 |
-1.36,
p=0.06 |
0.02,
p=0.37 |
-0.77, p=0.90 |
-7.03, p=0.01 |
-1.73, p<0.01 |
-0.32, p=0.86 |
-26.35, p=0.02 |
0.18, p=0.18 |
-2.51, p=0.28 |
-1.93, p=0.16 |
4.90, p<0.01 |
| Tumor necrosis factor-α receptor 1 |
-0.07,
p=0.51 |
0.44,
p=0.95 |
0.14,
p=0.01 |
1.30, p=0.77 |
-17.83, p=0.07 |
-2.12, p=0.06 |
-12.02, p=0.34 |
-19.54, p=0.40 |
-0.04, p=0.96 |
-9.40, p=0.05 |
-5.12, p=0.05 |
7.70, p=0.11 |
| Soluble CD163 |
-0.11,
p=0.20 |
-6.01,
p=0.40 |
-0.04, p=0.46 |
0.02, p=0.70 |
5.75, p=0.39 |
-0.79, p=0.60 |
11.60, p=0.23 |
-20.80, p=0.33 |
0.25, p=0.18 |
2.06, p=0.26 |
0.70, p=0.34 |
4.82, p=0.21 |
| Soluble CD14 |
0.00,
p=0.95 |
-13.88, p=0.10 |
-0.04, p=0.67 |
6.62, p=0.19 |
12.34, p=0.43 |
-1.70, p=0.46 |
-5.34, p=0.78 |
-46.00, p=0.24 |
0.19, p=0.58 |
-9.04, p=0.17 |
-5.53, p=0.11 |
15.52, p<0.01 |
| Results from linear mixed models pooling data across both recruitment and 12 weeks of ART. Models adjusted for age, sex, and baseline CD4+ T-cell count and included a random effect for patient. Bold values represent statistically significant findings.
Abbreviation: QTC: Corrected QT interval; RMSSD: Root Mean Square of the Successive Differences
Reactive hyperemia index is natural log transformed |
|
